Pfizer Inc. has received a request for additional information from the US Federal Trade Commission (FTC) with respect to its previously announced proposed $17 billion acquisition of Hospira, a provider of sterile injectables and infusion technologies. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, according to the company.

Completion of the transaction remains subject to the expiration of the waiting period under the HSR Act, governmental and regulatory approvals in certain other jurisdictions, and other usual and customary closing conditions. Pfizer and Hospira continue to expect the transaction to close in the second half of 2015.

Pfizer had announced in February 2015 that it had agreed to acquire Hospira for approximately $17 billion.

Source: Pfizer